Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

8.470 +0.070 (+0.83%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	522,746
Open	8.520
Bid (Size)	8.350 (100)
Ask (Size)	10.50 (1,500)
Prev. Close	8.400
Today's Range	8.370 - 8.790
52wk Range	3.365 - 12.34
Shares Outstanding	42,052,980
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy ↗

May 16, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage...

Via MarketBeat

4DMT Announces New Employment Inducement Grants

May 15, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+15.7%	+15.7%
1 Month	-15.9%	-15.9%
3 Month	-10.7%	-10.7%
6 Month	-16.1%	-16.1%
1 Year	+122.9%	+122.9%

More News

4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress ↗

May 07, 2026

Via Chartmill

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 07, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease ↗

November 06, 2025

Via Stocktwits

4DMT to Participate in Upcoming Investor Conferences

May 04, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

March 18, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Meetings

March 16, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Upcoming Investor Conferences

February 19, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

February 13, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

February 09, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

January 17, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Provides Company Update and Anticipated Development Milestones for 2026

January 07, 2026

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

December 17, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

December 12, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 08, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in 8th Annual Evercore Healthcare Conference

November 20, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Appoints Kristian Humer as Chief Financial Officer

November 17, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces New Employment Inducement Grants

November 14, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

November 10, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT to Participate in Jefferies 2025 London Healthcare Conference

November 06, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 06, 2025

Via Benzinga

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

November 06, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

November 06, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

October 30, 2025

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?

Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?

4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?

The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market

What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?

The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 8.470

When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?

The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 05/20/26 04:00 PM ET

What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?

The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 356.19M

How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?

4D Molecular Therapeutics, Inc. - Common Stock has 356M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.